

Contents

Introduction *XIII*

Glossary and Abbreviations *XV*

Part I Introduction *1*

1	The Drug Discovery Process	3
1.1	Pharmacokinetics–Structure Relationship	5
1.2	The Future of Small-Molecule Drugs	9
	References	11
2	Lead Optimization	13
2.1	What Limits/Reduces Oral Bioavailability?	14
2.2	What Limits/Reduces Plasma Half-Life?	15
2.3	How to Improve bbb-Penetration?	16
2.4	How to Avoid CYP Inhibition/Induction?	16
2.5	How to Avoid Interaction with the Human Ether-à-go-go-Related Gene (hERG)?	17
2.6	How to Prevent Toxicity?	17
2.7	Examples of PK-Optimization in Animals	20
2.7.1	Dihydroorotate Dehydrogenase Inhibitors	20
2.7.2	Matrix Metalloproteinase Inhibitors	21
2.7.3	Antibacterial Aminobenzenesulfonamides	21
2.7.4	Tyrosine Kinase Inhibitors	22
2.7.5	5-HT _{1A} Agonists	23
2.7.6	Dipeptidyl Peptidase IV Inhibitors; Structural Variations of Sitagliptin	23
2.7.7	P-Selectin Inhibitors	24
2.7.8	β ₃ -Adrenergic Agonists	24
2.7.9	Vanilloid-1 Antagonists	25
2.7.10	HIV Protease Inhibitors	25
2.7.11	Matrix Metalloproteinase Inhibitors (Tested in Rats)	26
2.7.12	HIV Integrase Inhibitors	26
2.7.13	Dopamine D ₃ Antagonists	27
2.7.14	Inhibitors of Soluble Epoxide Hydrolase (Tested in Mice, po)	28

2.7.15	Melanin-Concentrating Hormone Receptor-1 Antagonists	29
	References	29

Part II The Pharmacokinetic Properties of Compound Classes 33

3	Alkanes	35
3.1	Metabolism	36
	References	39
4	Alkenes and Alkynes	40
4.1	Metabolism	40
	References	44
5	Arenes	45
5.1	Metabolism	45
6	Halides	49
6.1	Fluorine	49
6.2	Chlorine	51
6.3	Bromine	53
6.4	Iodine	53
6.5	Alkylating Agents	54
	Reference	55
7	Azides	58
8	Nitro Compounds	59
8.1	Metabolism	60
9	Azo Compounds	62
10	Triazenes	64
11	Nitrates and Nitrites	66
	Further Reading	67
12	N-Nitroso Compounds	68
13	N-Oxides	70
14	Alcohols	71
14.1	Metabolism	72

15	Phenols	82
	References	84
16	Ethers	91
16.1	Metabolism	92
	Reference	93
17	Epoxides	96
18	Peroxides	97
19	Thiols	98
20	Thioethers	100
20.1	Metabolism	101
	Reference	103
21	Sulfoxides	104
22	Sulfones	106
23	Aliphatic Amines	107
23.1	Basicity	110
23.2	Metabolism	110
23.3	Rates of N-Dealkylation	112
	Reference	114
24	Quaternary Ammonium Salts	118
	Reference	119
25	Amidines	120
	Reference	121
26	Guanidines, Acylguanidines, and Biguanides	122
26.1	Acylguanidines	123
26.2	Biguanides	123
	Reference	124
27	Anilines	133
27.1	Metabolism	135
28	Hydrazines, Acylhydrazines, and Hydrazones	137

29	Aldehydes	138
30	Ketones	139
31	Carboxylic Acids	144
31.1	Metabolism	145
31.2	Bioisosteres of Carboxylic Acids	146
31.3	Amino Carboxylic Acids, <i>N</i> -Acyl Amino Acids, and Related Compounds	147
	References	148
32	Carboxylic Esters	164
	Reference	165
33	Amides	166
34	Lactams and Imides	172
34.1	Pyrazolone Antipyretics	172
34.2	Five-Membered Lactams as Nootropics	173
	References	174
35	Nitriles	184
	References	185
36	Carbonates	186
37	Carbamates	187
37.1	Carbamates as Hypnotics	188
	References	189
38	Ureas	192
	Reference	193
39	Thiocarbonyl Compounds	201
40	Sulfonic Acids	203
41	Sulfonic Esters	206
42	Sulfates and Sulfamic Acids	207
43	Phosphonic Acids	209

44	Phosphoric Acid Derivatives	213
45	N-(Aminoalkyl)benzamides, -Benzoates, and Related Compounds	215
	Reference	216
46	Arylalkylamines	225
46.1	Antihistaminics: History	225
	Reference	226
47	Phenethylamines (2-Phenylethylamines)	267
47.1	Biological Activity of Phenethylamines	267
47.2	Metabolism	268
47.3	Tetrahydroisochinolines and Related Compounds	269
	Further Reading	270
48	Aminoalkylindoles and Indole Alkaloids	291
	Reference	291
49	Phenothiazines	301
49.1	Metabolism	302
	References	302
50	Dibenzazepines and Related Tricyclic Compounds	310
51	3-Aryloxy-2-Hydroxypropylamines (β-Adrenergic Antagonists; “β-Blockers”)	320
51.1	Metabolism	320
52	Opiates	329
	Reference	329
53	N-(Carboxyalkyl)-α-Amino Acid Amides (Prils)	335
	Reference	336
54	Anilides and Amides of Glycine	341
55	Peptides, Peptidomimetics, and Related Oligoamides	347
55.1	Peptidomimetics	348
55.2	Thrombin Inhibitors and Related Compounds	349
	References	350

56	Oligoarylamines, Oligoarylamides, Oligoarylcarbamates, and Oligoarylureas	365
	References	365
57	Imidazoles	377
	References	378
58	Triazoles	387
59	Pyridines, Pyrimidines, and Related Compounds	393
59.1	Proton Pump Inhibitors	396
	References	397
60	Quinolines	412
60.1	Tecans	415
60.2	Quinazolines	415
	References	416
61	Nucleoside Analogs	428
	Reference	428
62	Dihydropyridines	446
63	Arenesulfonamides	450
63.1	Antibacterials	450
63.2	Diuretics	450
	Reference	451
64	Sulfonylureas	462
65	Benzodiazepines	466
	Reference	467
66	Steroids	477
	References	478
67	Anthracyclines	492
68	Arylacetic, Benzoic, and Related Carboxylic Acids (NSAIDS)	497
68.1	Salicylates	497
	References	498

69	Quinolonecarboxylic Acids (Gyrase Inhibitors)	514
70	β-Lactams	522
70.1	Cephalosporins	523
	Reference	523
71	Prostaglandin Analogs	538
72	Sartans	543
	Reference	544
73	Statins	548
74	Folic Acid Analogs (Antifolates)	551
75	Taxanes	554
	Reference	554
76	Macrocyclic Compounds	557
	Reference	557
	Index	567